Sanofi

Centelion

Aventis Pharma S.a.

Béatrice Cameron

Tarik Dabdoubi

Francis Blanche

Cendrine Lemoine

Catherine Prades

Gary J Nabel

Ling Xu

Zhi-Yong Yang

Lan Wu

Edward Seung

Daniel Scherman

Hervé Bouchard

Ronnie Rong Wei

Joël Crouzet

Pierre Wils

Joerg Thomas Regula

Huawei Qiu

Ercole Rao

Joerg Birkenfeld

Christian Lange

Vincent Mikol

Jochen Kruip

Christian Beil

Carsten Corvey

Nicolas Baurin

Martin Lorenz

Laurent Pradier

Christian Engel

Ingo Focken

Jochen Beninga

Thomas Langer

Horst Blum

Elizabeth Allen

Renata Lee

Norman Ruetsch

Thomas Oligino

Corentin Herbert

Marc Duchesne

Alexey Rak

Magali Mathieu

Katja Kroll

Françoise Bono

Stéphanie Decary

Paul Ferrari

Pierre-Francois Berne

Angela Virone-Oddos

Elisabeth Remy

Souad Naimi

Peter Wonerow

Yi Shi

Françis Blanche

Peter Florian

Zhen Xing

Sylvie Sordello

Marc Trombe

Mark Nesbit

Marielle Chiron Blondel

Brian Murray

Jonathan Kingsbury

Nathan Ostberg

Sanket Patke

Zichuan Zhang

Ronnie Wei

Yves Baudat

Anne-Marie LeFebvre

Ana Merino-Trigo

Manoel Nunes

David Papin

Céline Nicolazzi

Jacques Dumas

Alain Fournier

Anne-Marie Lefebvre

Pierre-François Berne

Provided herein are trispecific and/or trivalent binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind one or more target proteins, wherein a first pair of polypeptides forming the binding protein possess dual variable domains having a cross-over orientation, and wherein and a second pair of polypeptides possess a single variable domain forming a single antigen binding site. In some embodiments, the binding proteins comprise a binding site that binds a CD28 polypeptide, a binding site that binds a CD3 polypeptide, and a binding site that binds a third polypeptide, such as a tumor target protein. In some embodiments, the binding proteins comprise four polypeptide chains that form three antigen binding sites that specifically bind one or more HIV target proteins. The disclosure also relates to methods for making trispecific and/or trivalent binding proteins and uses of such binding proteins.

Trispecific binding proteins, methods, and uses thereof

Provided herein are antibodies that specifically bind human CD38, formulations and unit dosage forms comprising the antibodies, methods of preparing the antibodies and methods of using the antibodies.

Anti-CD38 antibodies and formulations

The disclosure provides methods of treating viral infection using trispecific binding proteins comprising four polypeptide chains that form three antigen binding sites that specifically bind a CD38 polypeptide (e.g., human and/or cynomolgus monkey CD38 polypeptides), a CD28 polypeptide, and a CD3 polypeptide.

Trispecific anti-CD38, anti-CD28, and anti-CD3 binding proteins and methods of use for treating viral infection

The disclosure provides binding proteins that bind CD38 polypeptides, e.g., human and cynomolgus monkey CD38 polypeptides. For example, the binding proteins can be monospecific, bispecific, or trispecific binding proteins with at least one antigen binding domain that binds a CD38 polypeptide. The disclosure also provides methods for making binding proteins that bind CD38 polypeptides and uses of such binding proteins.

Anti-CD38 antibodies and methods of use

Disclosed are antibodies which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also disclosed are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and pharmaceutical compositions comprising the antibodies or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Anti-CEACAM5 antibodies and uses thereof

Antibodies are provided which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding the antibodies. Also provided are immunoconjugates comprising the antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising the antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates are used for the treatment of cancer or for diagnostic purposes.

Antibodies are provided which specifically bind human andlysosomal-associated membrane protein 1 (LAMP1) proteins and immunoconjugates comprising said antibodies conjugated or linked to a growth inhibitory agent. Pharmaceutical compositions comprising antibodies or immunoconjugates of the invention and use of the antibodies or immunoconjugates for the treatment of cancer are also provided, as well as LAMP1 antibodies, isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies and the use of said antibody as a diagnostic tool. The application further provides for the detection of LAMP1 gene amplification or gain in cancer cells leading to the determination if patients with cancer are likely to respond to anti-LAMP1 therapy. Anti-LAMP1 therapeutic agent for use for treating cancer in a patient harboring LAMP1 gene copy number gain in cancer cells is further provided.

Anti-LAMP1 antibodies and antibody drug conjugates, and uses thereof

The present invention discloses antibodies which bind human andCEACAM5 proteins, as well as isolated nucleic acids, vectors and host cells comprising a sequence encoding said antibodies. The invention also discloses immunoconjugates comprising said antibodies conjugated or linked to a growth-inhibitory agent, and to pharmaceutical compositions comprising antibodies, or immunoconjugates of the invention. The antibodies or immunoconjugates of the invention are used for the treatment of cancer or for diagnostic purposes.

The present invention relates to a peptide or peptide complex binding to &#x3b1;2 integrin, to one or more nucleic acid(s) coding for the peptide or peptide complex, a recombinant cell producing the peptide or peptide complex, a method for producing the peptide or peptide complex, a pharmaceutical composition comprising the peptide or peptide complex or the nucleic acid(s) for use as a medicament, a method for detecting &#x3b1;2 integrin and a screening method.

Peptide or peptide complex binding to ALPHA2 integrin and methods and uses involving the same

The invention relates to modified soluble FGF receptor Fc fusions comprising a fusion of a soluble fragment or domain of the FGF receptor part (targeting or binding moiety) with an Fc region of an immunoglobulin part (effector function moiety), having improved biological activity including ADCC/CDC activities, compositions containing them, and method of producing such modified soluble FGF receptor Fc fusion molecules.

Modified soluble FGF receptor Fc fusions method

A method for double-stranded DNA purification, by which a solution containing DNA in a mixture with other components is passed over a support on which is covalently coupled an oligonucleotide capable of hybridizing with a specific sequence present on the DNA to form a triple helix.

Purification of a triple helix formation with an immobilized obligonucleotide

Purification of a triple helix formation with an immobilized oligonucleotide

The present invention relates to novel target double-stranded DNA sequences capable of interacting with a third strand and of forming a stable triple helix. The present invention also relates to a process for purifying a double-stranded DNA molecule, according to which a solution containing said DNA molecule is brought into contact with a third DNA strand capable of forming, by hybridization, a triple helix structure with a target double-stranded DNA sequence carried by said DNA molecule.

Processes for purifying and for detecting target double-stranded DNA sequences by triple helix interaction

Growing community of inventors

Paris, France

Béatrice Cameron